Medicine and Dentistry
Positron Emission Tomography-Computed Tomography
100%
Cancer Staging
100%
Colon Carcinoma
100%
Tissue Inhibitor of Metalloproteinase 1
37%
Recurrent Disease
25%
Diagnostic Accuracy
25%
Neoplasm
12%
Carcinoembryonic Antigen
12%
Metastatic Carcinoma
12%
Urokinase Receptor
12%
Fluorodeoxyglucose F 18
12%
Diseases
12%
Overall Survival
12%
Keyphrases
Positron Emission Tomography-computed Tomography (PET-CT)
100%
Confidence Interval
100%
Tissue Inhibitor of metalloproteinase-1 (TIMP-1)
30%
Colon Cancer
30%
Diagnostic Accuracy
20%
Primary Colon Cancer
20%
Extent of Disease
10%
Computed Tomography Examination
10%
Preoperative Staging
10%
Optimal Management
10%
2-deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography
10%
Metastasis
10%
Relapse Incidence
10%
Prognostic Information
10%
Patient Selection
10%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
10%
Carcinoembryonic Antigen
10%
Overall Survival
10%
Colon Cancer Patients
10%
Recurrence Risk
10%
Tumor
10%
Agricultural and Biological Sciences
Positron-Emission Tomography
100%
Computed Tomography
100%
Confidence Interval
100%
Colon
100%
Metalloprotease Inhibitor
30%
Urokinase Receptor
10%
Carcinoembryonic Antigen
10%
Biochemistry, Genetics and Molecular Biology
Cancer Staging
100%
Positron Emission Tomography-Computed Tomography
100%
Colon
100%
Metalloprotease Inhibitor
37%
Urokinase Receptor
12%
Carcinoembryonic Antigen
12%
Overall Survival
12%
Pharmacology, Toxicology and Pharmaceutical Science
Colon Carcinoma
100%
Cancer Staging
100%
Tissue Inhibitor of Metalloproteinase 1
42%
Recurrent Disease
28%
Carcinoembryonic Antigen
14%
Diseases
14%
Neoplasm
14%
Fluorodeoxyglucose F 18
14%
Overall Survival
14%
Urokinase Receptor
14%
Neuroscience
Positron Emission Tomography-Computed Tomography
100%
Metalloprotease Inhibitor
37%
Urokinase Receptor
12%
Fluorine-18
12%
Carcinoembryonic Antigen
12%